Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

Iron Deficiency Anemia Clinical Trial

Official title:

Salivary Cystatin SN Binds to Phytic Acid and is a Predictor of Non-heme Iron Bioavailability With Phytic Acid Supplementation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03030703
• Other study ID #: SPPhyticAcidTrial
• Status: Completed
• Phase: N/A
• First received: January 23, 2017
• Last updated: January 24, 2017
• Start date: November 11, 2016
• Est. completion date: December 10, 2016

Study information

• Verified date: January 2017
• Source: Kansas State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phytic acid is a known inhibitor of iron bioavailability, although long term studies have suggested possibly exaggerated findings compared to single meal studies, pointing to phytic acid adaptation over time. Salivary proline-rich proteins have been found to reduce tannin-iron chelation, but studies have not explored changes in salivary proteins that may result in phytic acid adaptation. The primary objectives of this study are: 1) To determine whether phytic acid impacts iron bioavailability or status when consumed over time 2) to test whether salivary protein production may impact iron bioavailability with phytic acid supplementation, and 3) to explore in vitro phytic acid salivary binding. Secondary objectives included assessment of the reliability of astringency as a measure of salivary protein production and iron absorption.

The study was conducted in an iron absorption study of 7 women, aged 18-35 years old, to determine iron bioavailability with supplementation of 350 mg phytic acid before and after regular, three times daily supplementation for four weeks. Direct iron absorption was measured using area under the curve. Iron status was measured by changes in hemoglobin and ferritin, and was adjusted by participant c-reactive protein levels. Salivary samples were collected before and after supplement consumption during meal challenges, and analyzed on HPLC and by ELISA. Astringency testing was conducted at the end of each meal challenge. In vitro saliva-phytic acid modeling was explored on HPLC, MALDI-TOF, and ELISA. Iron absorption and status markers were analyzed by ANOVA, and mixed-modeling followed by pairwise comparison by least significant differences. Pearson's correlations were used to correlated salivary proteins and astringency with iron bioavailability.

The present study will provide important information regarding the approximate influence of phytic acid consumption on iron bioavailability and storage over time in regards to salivary proteins. It will also give context to the role of salivary proteins with phytic acid consumption over time. Data will also help to delineate possible physiological mechanisms underlying phytic acid adaptation and possible ways to detect individuals who better adapt than others.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: December 10, 2016
• Est. primary completion date: December 10, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Female, 18-35 years' old

• Non-obese BMI (18-29.9)

• Signed informed consent

Exclusion Criteria:

• Oral disease

• Gastrointestinal disease

• Tobacco user

• Heavy alcohol user

• Pregnancy (assessed by pregnancy test)

• Lactation

• Medications affecting iron bioavailability

• Vitamin or mineral supplementation (other than vitamin B12)

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Iron Deficiency Anemia
• Iron-deficiency

Intervention

Dietary Supplement:
• phytic acid
350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks

Locations

Country	Name	City	State
United States	Physical Activity and Nutrition Research Consortium	Manhattan	Kansas

Sponsors (3)

Lead Sponsor	Collaborator
Kansas State University	American Academy of Nurse Practitioners, United States Department of Agriculture Foreign Agricultural Service

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in baseline to endline area under the curve after meal challenge at weeks 0 and 4 of intervention	Change in area under the curve will be measured after administration of test meal including ferrous sulfate and condensed tannin supplementation at weeks 0 and 4	Baseline and 4 weeks
Primary	Change in baseline to endline hemoglobin and serum ferritin at weeks 0 and 4 of intervention	Change in ferritin and hemoglobin will be measured before administration of test meals at weeks 0 and 4	Baseline and 4 weeks
Primary	Change in salivary proteins at weeks 0 and 4 of intervention	HPLC determination of salivary proteins will be analyzed from saliva collected before and after test meals at weeks 0 and 4 of the intervention	Baseline and 4 weeks